Aeterna Zentaris Inc

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology and endocrinology. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. Show More...

  • Website http://www.zentaris.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 5.10 CAD
  • Last Updated 11-10-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -226.0 -172.0 -103.06 23.12 -28.06 -18.14 -2.41 -1.12 0.24 -0.35 -0.010
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 3.0 10.0 15.0 17.0 17.0 19.0
    Book Value Per Share * CAD 89.47 -23.78 -26.3 41.35 13.12 1.79 0.34 -0.15 0.61 -0.14 0.1
    Free Cash Flow Per Share * CAD -247.48 -179.22 -156.39 -131.57 -42.73 -39.53 -4.02 -2.37 0.41 -0.79
    Return on Assets % -28.52 -35.63 -28.54 10.74 -31.07 -101.37 -60.03 -62.38 17.74 -26.86 -1.68
    Financial Leverage (Average) 6.15 3.47 3.27 2.38 5.1 13.12 11.64
    Return on Equity % -214.34 -685.85 131.45 -105.01 -277.81 -179.39 -979.64
    Return on Invested Capital % -216.01 -790.05 127.88 -105.81 -278.6 -180.47 -983.27
    Interest Coverage -892.0 -52.43 -9.51 0.39
    Current Ratio 3.28 3.36 3.39 6.3 4.78 6.6 5.41 1.63 2.9 1.93 3.46
    Quick Ratio 2.92 3.09 3.03 6.24 4.73 6.54 5.32 1.39 2.65 1.5 3.09
    Debt/Equity 0.09